The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Samuel Broder named executive VP at Intrexon Corporation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

SAMUEL BRODER was named executive vice president of scientific and public affairs at the Intrexon Corporation. The former director of NCI was most recently chairman of Intrexon’s health sector.

Broder will lead the company’s communications programs with media, academia, government, and non-profit organizations, spanning health, food, energy, environment, and consumer sectors.

YOU MAY BE INTERESTED IN

Trials & Tribulations

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
By Ashley Cannon

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account